Lixivaptan

Generic Name: Lixivaptan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₁ClFN_₃O_₂

CAS Number: 168079-32-1

Unique Ingredient Identifier: 8F5X4B082E

Indication: Investigated for use/treatment in hyponatremia and congestive heart failure.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Phase 3

Terminated

Conditions: Polycystic Kidney Disease, Adult

Interventions: Drug: Lixivaptan

First Posted Date: 2022-01-26

Last Posted Date: 2023-05-12

Lead Sponsor: Palladio Biosciences

Target Recruit Count: 1

Registration Number: NCT05208866

Locations: 🇺🇸
Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Phase 3

Terminated

Conditions: ADPKD
Polycystic Kidney Disease, Adult

Interventions: Drug: Lixivaptan

First Posted Date: 2019-11-05

Last Posted Date: 2023-04-10

Lead Sponsor: Palladio Biosciences

Target Recruit Count: 7

Registration Number: NCT04152837

Locations: 🇺🇸
Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago Medicine & Biological Sciences, Chicago, Illinois, United States

and more 3 locations

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Phase 3

Terminated

Conditions: ADPKD
Autosomal Dominant Polycystic Kidney

Interventions: Drug: Lixivaptan
Drug: Placebo

First Posted Date: 2019-08-21

Last Posted Date: 2023-02-06

Lead Sponsor: Palladio Biosciences

Target Recruit Count: 12

Registration Number: NCT04064346

Locations: 🇺🇸
Prolato Clinical Research Center (PCRC), Houston, Texas, United States
🇺🇸
Total Research Group, LLC, Miami, Florida, United States
🇧🇬
University Multiprofile Hospital for Active Treatment, Pleven, Bulgaria

and more 40 locations

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Conditions: Polycystic Kidney

First Posted Date: 2018-10-24

Last Posted Date: 2021-10-14

Lead Sponsor: Palladio Biosciences

Registration Number: NCT03717181

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Phase 2

Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease

Interventions: Drug: Lixivaptan

First Posted Date: 2018-04-04

Last Posted Date: 2022-12-05

Lead Sponsor: Palladio Biosciences

Target Recruit Count: 31

Registration Number: NCT03487913

Locations: 🇺🇸
Palladio Biosciences Clinical Site, Salt Lake City, Utah, United States

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Lixivaptan

First Posted Date: 2010-01-26

Last Posted Date: 2011-06-28

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 170

Registration Number: NCT01055912

Locations: 🇺🇸
Innovative Research of West Florida, Inc, Clearwater, Florida, United States
🇺🇸
Charlotte Heart Group Research Center, Port Charlotte, Florida, United States
🇺🇸
Capitol Interventional Cardiology, Carmichael, California, United States

and more 22 locations

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Phase 3

Completed

Conditions: Euvolemic Hyponatremia

Interventions: Drug: Placebo
Drug: Lixivaptan

First Posted Date: 2009-04-07

Last Posted Date: 2011-06-28

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 206

Registration Number: NCT00876798

Locations: 🇺🇸
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸
Galiz Research, Miami, Florida, United States
🇺🇸
Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States

and more 86 locations

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Phase 3

Withdrawn

Conditions: Hypervolemic Hyponatremia

Interventions: Drug: Lixivaptan

First Posted Date: 2009-04-07

Last Posted Date: 2010-11-23

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 300

Registration Number: NCT00876876

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: placebo
Drug: lixivaptan
Drug: moxifloxacin

First Posted Date: 2008-05-12

Last Posted Date: 2011-06-21

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 298

Registration Number: NCT00675701

Locations: 🇺🇸
Research Site 1, Austin, Texas, United States

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Phase 3

Completed

Conditions: Hyponatremia With Normal Extracellular Fluid Volume

Interventions: Drug: lixivaptan
Drug: placebo

First Posted Date: 2008-04-18

Last Posted Date: 2011-06-28

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 106

Registration Number: NCT00660959

Locations: 🇮🇳
Poona Hospital and Research Centre, Pune, Maharashtra, India
🇺🇸
RTR Medical Group, Savannah, Georgia, United States
🇺🇸
Four Rivers Clinical Research, Inc., Paducah, Kentucky, United States

and more 27 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy